Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study. The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice. The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome. The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2. The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC. The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer. The final segment of this roundtable series discusses radiopharmaceuticals and PARP inhibitors. Part five of this roundtable series covers data and insights from the ARANOTE and PEACE 3 trials. Part four of a PCa roundtable series focuses on the effectiveness of ADT with triplet therapy. Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024. The first part of five segments from the Uromigos Live 2024 session on radioligands. 18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer. The primary endpoint of rPFS was maintained in both cohorts. Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment. The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases. Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial. Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy. In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease. In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed. In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.